Evidence map›Paper›PMID 33076217›Full record

Trial reportNutrients2020

Long Term Dietary Restriction of Advanced Glycation End-Products (AGEs) in Older Adults with Type 2 Diabetes Is Feasible and Efficacious-Results from a Pilot RCT.

Roni Lotan, Ithamar Ganmore, Shahar Shelly, Moran Zacharia, Jaime Uribarri, Paul Beisswenger, Weijing Cai, Aron M Troen, Michal Schnaider Beeri

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02739971 (Dietary Reduction of Advanced Glycation End Products to Prevent Cognitive Decline in Elderly Diabetics - a Randomized Pilot Trial), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02739971 nacompletednot on this map

Dietary Reduction of Advanced Glycation End Products to Prevent Cognitive Decline in Elderly Diabetics - a Randomized Pilot Trial

TypeinterventionalSponsorSheba Medical CenterRan2016 to 2020Enrolled75ConditionsCognitive Decline, Aging, Type 2 DiabetesArmsLow AGEs diet, Standard of care dietary guidance for Type 2 diabetes
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  4. Meloxicam mitigated methylglyoxal-induced glycative stress in rats.Iranian journal of basic medical sciences · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Roni LotanThe Nutrition and Brain Health Laboratory, The Institute of Biochemistry, Food and Nutrition Science, The Robert H. Smith Faculty of Agriculture Food and the Environment, The Hebrew University of Jerusalem, 7610001 Rehovot, Israel.
Ithamar GanmoreThe Joseph Sagol Neuroscience Center, Sheba Medical Center, 5265601 Tel Hashomer, Israel.
Shahar ShellyThe Joseph Sagol Neuroscience Center, Sheba Medical Center, 5265601 Tel Hashomer, Israel.ORCID 0000-0002-3585-1687
Moran ZachariaThe Joseph Sagol Neuroscience Center, Sheba Medical Center, 5265601 Tel Hashomer, Israel.
Jaime UribarriIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Paul BeisswengerPreventAGE Healthcare, Lebanon, NH 03766, USA.
Weijing CaiIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Aron M TroenThe Nutrition and Brain Health Laboratory, The Institute of Biochemistry, Food and Nutrition Science, The Robert H. Smith Faculty of Agriculture Food and the Environment, The Hebrew University of Jerusalem, 7610001 Rehovot, Israel.ORCID 0000-0001-9738-2524
Michal Schnaider BeeriThe Joseph Sagol Neuroscience Center, Sheba Medical Center, 5265601 Tel Hashomer, Israel.
Hebrew University of Jerusalem · ILIcahn School of Medicine at Mount Sinai · USSheba Medical Center · ILMayo Clinic · USPreventAGE Health Care (United States) · USTel Aviv University · IL

Funding

Katzin Foundation 45126
6 · The paper itself

Abstract

introductionHigh serum concentrations of advanced glycation end-products (AGEs) in older adults and diabetics are associated with an increased risk of cognitive impairment. The aim of this pilot study was to assess the feasibility of long-term adherence to a dietary intervention designed to decrease intake and exposure to circulating AGEs among older adults with type 2 diabetes.

methodsHerein, 75 participants were randomized to either a standard of care (SOC) control arm or to an intervention arm receiving instruction on reducing dietary AGEs intake. The primary outcome was a change in serum AGEs at the end of the intervention. Secondary and exploratory outcomes included adherence to diet and its association with circulating AGEs. Cognitive function and brain imaging were also assessed but were out of the scope of this article (ClinicalTrials.gov Identifier: NCT02739971).

resultsThe intervention resulted in a significant change over time in several serum AGEs compared to the SOC guidelines. Very high adherence (above 80%) to the AGE-lowering diet was associated with a greater reduction in serum AGEs levels. There were no significant differences between the two arms in any other metabolic markers.

conclusionsA long-term dietary intervention to reduce circulating AGEs is feasible in older adults with type 2 diabetes, especially in those who are highly adherent to the AGE-lowering diet.

Indexed as

Diet TherapyAgedAge FactorsCognitive DysfunctionDiabetes Mellitus, Type 2EatingFeasibility StudiesFemaleGlycation End Products, AdvancedHumansMalePilot ProjectsTime FactorsGlycation End Products, Advancedadherenceadvanced glycation end-productsdietrandomized controlled trialtype 2 diabetes

Identifiers

PMID33076217
PMCPMC7602440
OpenAlexW3093054454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.